Bortezomib is a known inhibitor of the NF-κB signaling pathway, and the activation of NF-κB was shown to suppress autophagy.35 If this is the case, then bortezomib should activate autophagy and eliminate p62.23 However, bortezomib inhibited the NF-κB signaling pathway in seven ovarian cancer lines by increasing IκB phosphorylation, but also increased p62 levels in eight ovarian cancer cells (Supplementary Figure 3). Here, NFKB1 is linked to ovarian cancer.